Novavax to Present RSV Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26

GAITHERSBURG, Md., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Gregory Glenn, M.D., Senior Vice President, Research and Development at Novavax will present new immunogenicity data from Novavax' RSV F-Protein Nanoparticle vaccine candidate (RSV F vaccine) clinical trials at the 8th...

New York, 23/10/2014 (informazione.it - comunicati stampa - scienza e tecnologia)
Copyright GlobeNewswire


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire